84254-39-7

Basic information

• Product Name: 3,5-di(N-β-phenethyl)carbamoylpyridine
• Synonyms: 3,5-di(N-β-phenethyl)carbamoylpyridine
• CAS NO: 84254-39-7
• Molecular Weight: 373.455
• Mol File: 84254-39-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3,5-di(N-β-phenethyl)carbamoylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-di(N-β-phenethyl)carbamoylpyridine(84254-39-7)
• EPA Substance Registry System: 3,5-di(N-β-phenethyl)carbamoylpyridine(84254-39-7)

Safety Data

• Hazardous Substances Data: 84254-39-7(Hazardous Substances Data)

Upstream product

• 499-81-0 3,5-Pyridinedicarboxylic acid 
• 64-04-0 phenethylamine 
• 4591-56-4 diethyl 3,5-pyridinedicarboxylate 

Downstream Products

• 84278-95-5 1-methyl-3,5-bis(N-phenethylcarbamoyl)pyridinium iodide 
• 617708-76-6 (3,5-bis-phenethylcarbamoyl-4H-pyridin-1-yl)-acetic acid ethyl ester 
• 617708-77-7 (3,5-bis-phenethylcarbamoyl-4H-pyridin-1-yl)-acetic acid isopropyl ester 
• 617708-78-8 (3,5-bis-phenethylcarbamoyl-4H-pyridin-1-yl)-acetic acid 

Relevant articles and documents

New carrier for specific delivery of drugs to the brain

1,4-Dihydropyridines were thoroughly investigated as carriers for specific drug delivery to the brain and were found very efficient. The main problem which arises in their application in pharmaceutical preparations, is the short shelf-life time due to hydration and/or oxidation. To overcome these problems, a new carrier system is suggested. Many of 1,4-dihydropyridine-3,5-dicarboxylate derivatives are used as calcium channel blockers which are known to have long shelf-life time, and at the same time, they are safe, with no reported neurotoxicity. Since efficiency of brain specific delivery depends on the rate of oxidation of the dihydropyridine carrier, (the faster the rate, the higher the efficiency), these 3,5-dicarbonyl compounds have almost of no brain-specific delivery properties. N-alkoxycarbonylmethyl derivatives of 1,4-dihydropyridine-3,5-dicarboxylate, a new carrier system is suggested and expected to be stable enough for formulation and storage. The drug moiety will be connected to the 3,5-dicarbonyl groups in the form of esters or amides. The suggested drug-carrier once delivered and distributed in the body, will be subjected to several sequential enzymatic hydrolytic and oxidative processes. The D-carrier is designed so that, the rate of hydrolysis of the ester group at the nitrogen atom should be faster than that of the hydrolysis and release of the drug moiety. The stability and efficiency of brain specific delivery of model drugs were investigated. The in vitro and in vivo studies proved the efficiency of brain specific delivery of the carrier and at the same time its shelf life stability. The results suggest that the designed carrier is promising to be used in application of pharmaceutical formulation.

Brain-specific drug delivery

The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine pyridinium salt redox carrier, with the proviso that when [DHC] is STR1 wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and (b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entities [D-QC]+ Y- are also disclosed.